CD8A and neoplasm: In line with these findings, IHC analysis of the tumor revealed that AB680+gemcitabine significantly decreased both the tumor‐infiltrating CD8+ T cells and MDSCs; In addition, no significant difference in the tumor‐infiltrating granzyme B+ cells among the treatment groups was identified (Figure S7I, Supporting Information).